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Abstract
The small- and intermediate-conductance Ca2+-activated potassium (SK/IK) channels play
important roles in the regulation of excitable cells in both the central nervous and cardiovascular systems. Evidence from animal models has implicated SK/IK channels in neurological
conditions such as ataxia and alcohol use disorders. Further, genome-wide association studies have suggested that cardiovascular abnormalities such as arrhythmias and hypertension
are associated with single nucleotide polymorphisms that occur within the genes encoding
the SK/IK channels. The Ca2+ sensitivity of the SK/IK channels stems from a constitutively
bound Ca2+-binding protein: calmodulin. Small-molecule positive modulators of SK/IK channels have been developed over the past decade, and recent structural studies have revealed
that the binding pocket of these positive modulators is located at the interface between the
channel and calmodulin. SK/IK channel positive modulators can potentiate channel activity
by enhancing the coupling between Ca2+ sensing via calmodulin and mechanical opening of
the channel. Here, we review binding pocket studies that have provided structural insight into
the mechanism of action for SK/IK channel positive modulators. These studies lay the foundation for structure-based drug discovery efforts that can identify novel SK/IK channel positive
modulators.
© 2014 S. Karger AG, Basel
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Introduction

The small- and intermediate-conductance Ca2+-activated potassium (SK/IK) channels
belong to a subfamily of Ca2+-activated potassium channels, which play important roles in the
regulation of membrane excitability by the intracellular Ca2+ [1]. SK/IK channels share the
same tetrameric architecture with the voltage-dependent potassium channels. Each channel
subunit is composed of six transmembrane α-helical domains that are denoted S1–S6. A loop
between the transmembrane S5 and S6 domains forms a potassium ion selectivity filter
(fig. 1).
Unlike the voltage-dependent potassium channels, SK/IK channel activation is not
voltage dependent. Instead, elevated intracellular Ca2+ levels that occur in response to
various physiological stimuli exclusively activate SK/IK channels. The Ca2+-binding protein
calmodulin (CaM) is constitutively associated with SK/IK channels at the CaM-binding
domain (CaMBD). The CaMBD is located in the proximal C-terminus of the channels (fig. 1).
Ca2+ binding to CaM induces conformational changes in both CaM and the CaMBD that subsequently trigger an opening of the channel pore [2–4]. The mechanism by which these conformational changes in CaM and CaMBD translate into channel opening has only recently been
elucidated.
In addition to intracellular elevated Ca2+ levels, the SK/IK channels are also subject to
regulation by posttranslational modification (e.g., phosphorylation). The Ca2+ sensitivity of
the SK/IK channels is reduced by phosphorylation of a specific CaM threonine residue (Thr79)
by casein kinase 2. Importantly, the phosphorylation status of CaM Thr79, and thus the Ca2+
sensitivity of the channels, is regulated by casein kinase 2 and protein phosphatase 2A. Both
are constitutively associated with the SK/IK channels [1].
Genes encoding SK/IK channels are highly conserved in many species including mammals,
Drosophila melanogaster and Caenorhabditis elegans. There are four mammalian genes that
encode the SK/IK channels: KCNN1 for SK1, KCNN2 for SK2, KCNN3 for SK3 and KCNN4 for IK
(also known as SK4) channels [1]. SK1–3 channels have small single-channel conductance
and are thus named ‘small-conductance’ channels. The protein encoded by KCNN4 has intermediate single-channel conductance and is accordingly denoted an ‘intermediate-conductance’ channel (table 1). SK1–3 channels are widely expressed in electrically excitable cells
including the central nervous and cardiovascular systems. IK channel expression in the
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Fig. 1. The architecture of one
SK/IK channel subunit. Each subunit has six α-helical transmembrane domains (S1–S6, pink). The
loop between the S5 and S6 domains forms the potassium ion filter. Both the N- and C-termini are
located on the intracellular side of
the membrane. The Ca2+-binding
protein CaM is associated with
the CaMBD that is located at the
proximal C-terminus of the SK/IK
channels. CaM serves as the Ca2+
sensor for the channels. In the absence of Ca2+, the CaM C-lobe
(blue), but not the N-lobe (red),
binds to the CaMBD.
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central nervous system is very low. However, in peripheral tissues, the IK channel is found in
the vascular endothelium, secretory epithelia and T cells [5].
Potassium efflux through SK/IK channels hyperpolarizes the cell. Accordingly, SK/IK
channels modulate cell excitability. In addition, SK and IK channels have been implicated in
multiple pathophysiological conditions such as ataxia, alcohol use disorders, Parkinson’s
disease and hypertension. As a result, these channels have been recognized as potential therapeutic drug targets [6, 7].
In this review, we first summarize clinical conditions that have been linked with SK/IK
channels in both the cardiovascular and central nervous systems. Then, we go on to review
the recent development of SK/IK channel positive modulators that have shown promise as
novel treatment options for ataxia, alcohol use disorders and hypertension. We next highlight
the recently discovered binding pocket and mechanism whereby small molecules can positively modulate the SK/IK channels. This mechanism was elucidated through combined
approaches including crystallography, molecular dynamic simulations, mutagenesis and
electrophysiology. Finally, the state of the art of structure-based discovery of novel drugs that
target the SK/IK channels will also be discussed.
SK/IK Channels in the Central Nervous System

Three subtypes of SK channels (SK1–3) are expressed in many areas of the central
nervous system. Their activation is specifically involved in afterhyperpolarization, which
regulates the firing frequency for many types of neurons [1]. In neurological diseases that
involve abnormal neuronal firing patterns, such as ataxia, Parkinson’s disease and alcohol use
disorders, the pharmacological manipulation that leads to SK channel activation can serve
neuroprotective roles.
The Cerebellum and Ataxia

Ataxia is a movement disorder characterized by a lack of coordination of muscle movements. Dysfunction of cerebellar Purkinje cells has been observed in many types of ataxia [8].
More specifically, the loss of firing precision by Purkinje cells is thought to underlie the
symptoms of episodic ataxia and spinal cerebellar ataxia [9, 10]. Moreover, aberrant Ca2+

Channel

Human gene

Single-channel
conductance, pS

Ca2+ sensitivity,
pEC50

Positive modulators

SK1

KCNN1

9.2

6.2 – 6.5

1-EBIO, DCEBIO, NS309, riluzole,
SKA-31, GW542573X

SK2

KCNN2

9.5

6.2 – 6.5

1-EBIO, DCEBIO, NS309, riluzole,
SKA-31, CyPPA, NS13001

SK3

KCNN3

–

6.0 – 6.5

1-EBIO, DCEBIO, NS309, riluzole,
SKA-31, CyPPA, NS13001

IK

KCNN4

11 – 40

6.1 – 7.0

1-EBIO, DCEBIO, NS309, riluzole,
SKA-31, SKA-111 [60]
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Table 1. Biophysical properties and positive modulators of SK and IK channels adapted from Aldrich et al. [71]
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influx during action potential generation (either a shortage or an overload) can lead to
dysfunction of Purkinje cell firing [11]. Pharmacological manipulations that restore the
regular firing pattern of Purkinje cells have been suggested as a means of alleviating ataxia
symptoms. The predominant SK channel subtype expressed by Purkinje cells is SK2, and SK2
has emerged as a major ion channel involved in Purkinje cell pacemaking [12]. SK channels
play important roles in the regulation of Purkinje cell excitability by modulating the afterhyperpolarization that occurs after action potential generation. Additionally, a positive modulation of SK channels can counteract genetic mutations that cause either reduced [13] or
elevated [14] Ca2+ signaling, and SK channel positive modulators can alleviate some behavioral and neuropathological symptoms of ataxia in animal models [10, 13, 15, 16]. Lastly,
riluzole, an SK/IK channel positive modulator, yielded promising results in a phase II clinical
study of a mixed population of ataxia patients [17].
The Substantia Nigra and Parkinson’s Disease

Parkinson’s disease is a neurodegenerative disorder without curative treatment. The
degeneration of midbrain substantia nigra dopaminergic neurons is thought to underlie the
pathogenesis of Parkinson’s disease. SK channels are also implicated in the physiology of
dopaminergic neurons [18]. For example, an SK3 mutation (hSK3Δ) that has been associated
with human disease (schizophrenia) generates a dominant negative for SK channels that
suppresses endogenous SK currents. The introduction of this hSK3Δ mutation into mouse
midbrain dopamine neurons reduced coupling between NMDA receptors and SK channels.
Consequently, the normally occurring balance between tonic and phasic dopaminergic
neuron activity was disrupted by the introduction of hSK3Δ [19]. In addition, a deletion of the
mouse KCNN2 gene that encodes SK2 led to mouse behavioral phenotypes that are thought
to model specific aspects of human Parkinson’s disease [20]. SK channels expressed on the
neuronal plasma membrane may exert neuroprotective effects through modulating the firing
pattern of dopaminergic neurons [21]. SK channels were also identified on the membrane of
mitochondria in dopaminergic neurons. The activation of mitochondrial SK channels could
prevent mitochondrial dysfunction [22]. As such, SK channels have been suggested as a
potential drug target for dopamine-neuron-related diseases, even though it is not clear
whether SK channel activity is altered in Parkinson’s disease patients [23]. Accordingly,
further evaluation of this hypothesis is needed.

Alcohol abuse and misuse continues to exhaust significant socioeconomic resources.
This is in part due to an increase in the motivation to seek alcohol that develops over time
and that persists during abstinence. It has been demonstrated that SK channels may play an
important role in the neurobiology of alcohol seeking [24]. For example, the expression and
function of SK3 channels is decreased in the rat nucleus accumbens core after abstinence
from ethanol self-administration [24] and in the ventral tegmental area after repeated
ethanol injections [25]. A similar reduction was seen ex vivo after the application of ethanol
to hippocampal slices [26]. This decrease in SK channel activity led to increased action
potential generation by both nucleus accumbens core and ventral tegmental area neurons.
Importantly, positive modulation of nucleus accumbens core neuron SK channels with
1-EBIO normalized neuronal firing and decreased the motivation of rats to self-administer
ethanol [24]. 1-EBIO can also reduce ethanol-induced hyperexcitability, neurotoxicity and
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handling-induced convulsions in mice [26]. Similarly, the FDA-approved SK channel positive
modulator chlorzoxazone decreased ethanol consumption in a rat model of high ethanol
intake [27], and CyPPA has been shown to reduce both ethanol consumption and the preference for ethanol over water in mice [28]. Unfortunately, chlorzoxazone failed to reduce the
number of drinks consumed per week in a clinical trial of 20 moderate-to-heavy social
alcohol users compared to placebo (NCT01342341). However, because chlorzoxazone has
off-target effects that confound an unequivocal interpretation of these studies, it remains to
be determined whether other more potent and selective SK channel positive modulators
would be clinically effective.
SK/IK Channels in the Cardiovascular System

In the normal heart, three SK channel subtypes are expressed (SK1, SK2 and SK3), and
these subtypes play important roles in regulating the activity of atrial myocytes [29–32].
Moreover, in vascular endothelial cells [33], the predominant subtypes are IK and SK3. SK2
channels are also expressed in endothelial cells, but to a lesser extent, whereas SK1 channels
are not expressed.
The Heart and Arrhythmias

The SK channels have emerged as major ion channels regulating cardiac action potentials. In the normal heart, SK channels are mostly expressed in the atria, while very little SK
channel expression is seen in the normal ventricles [29]. However, ventricular SK channel
activity is upregulated in the failing heart [34]. These data implicate a role of SK channels in
cardiac pathophysiology or perhaps a homeostatic role in the diseased ventricle. An increase
in both Ca2+ sensitivity and channel protein expression is thought to contribute to SK channel
upregulation [35]. It remains unknown whether casein kinase 2 and/or protein phosphatase
2A regulate the Ca2+ sensitivity of cardiomyocyte SK channels, and this regulatory mechanism
of phosphorylation/dephosphorylation needs further investigation.
Genetic studies also support a role of SK channels in arrhythmia. Genetic ablation of SK2
channels in mice resulted in atrial action potential prolongation and atrial arrhythmias [36].
Moreover, single nucleotide polymorphisms in the SK/IK genes have been implicated in
cardiovascular abnormalities [37, 38]. Lastly, single nucleotide polymorphisms in the SK3
gene (KCNN3) have been associated with lone atrial fibrillation [38].

SK/IK channels also play an equally important role in vascular system function [39–
43]. SK/IK channels are especially important in vasodilation that is mediated by endothelium-derived hyperpolarizing factor (EDHF) [44–46]. Activation of SK/IK channels in
endothelial cells can induce hyperpolarization that is transduced to smooth muscle cells
through the myoendothelial gap junctions. Using transgenic mice with suppressed expression of SK3 channels, it was found that SK3 channel expression can modulate both
arterial tone and blood pressure [39]. Further, a genetic deficiency of both SK3 and IK
channels in mice severely impaired both endothelial hyperpolarization and EDHF-mediated
vasodilation, which caused hypertension-like symptoms [47]. Additionally, SK3 expression
is reduced by more than 40% in mesenteric arteries from spontaneously hypertensive rats
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[48]. Similarly, decreased SK3 mRNA and protein expression was observed in mesenteric
arteries collected from rats with angiotensin-II-induced hypertension [49]. Accordingly, it
has been suggested that compromised SK channel activity may be a contributing factor to
hypertension [41].
Genome-wide association studies of single nucleotide polymorphisms occurring within
the IK channel locus revealed an association with myocardial infarction [50]. IK channels are
also implicated in atherogenesis in both mice and humans [51]. Additionally, a positive modulation of endothelial SK/IK channels can lower blood pressure in hypertension animal models.
These data, in part, led to the development of SKA-31, an SK/IK channel positive modulator
based on riluzole. SKA-31 can lower blood pressure by enhancing EDHF-mediated responses
[52]. Thus, SKA-31 illustrates the potential of SK/IK channels as potent therapeutic targets
for the treatment of hypertension.

Given the many roles of SK/IK channels in central nervous and cardiovascular system
functions, a great deal of effort has been devoted to developing small molecules that selectively target SK/IK channels [53]. The first positive modulator, 1-EBIO (1-ethyl-2-benzimidazolinone), was identified almost two decades ago [54]. 1-EBIO potentiates SK/IK channel
activity, which enhances afterhyperpolarization and effectively modulates neuronal excitability [55]. The structural optimization of 1-EBIO led to DCEBIO. Compared to 1-EBIO,
DCEBIO exhibits ∼20-fold higher potency [56]. In the past decade, a Scandinavian biopharmaceutical company (NeuroSearch A/S) has developed additional compounds that target the
SK/IK channels, including the potent SK/IK channel positive modulator NS309 [57].
Subtype-selective modulators have recently emerged for the SK/IK channels, and NeuroSearch A/S has developed several of these. For example, CyPPA is an SK2/SK3-selective
positive modulator [58], and NS13001 is an orally effective SK2/SK3-selective compound
that has shown promising beneficial effects in a mouse model of spinocerebellar ataxia type
2 [15]. Additionally, NeuroSearch A/S has also achieved a relatively selective activation of
SK1 channels with GW542573X. This compound exhibited 10 times higher potency at SK1
channels over SK2 and SK3 channels [59]. Others have generated IK channel-selective
compounds. Dr. Wulff’s group from the University of California at Davis recently synthesized
SKA-111, which displayed 160-fold selectivity for IK channels over SK3 channels [60]. The
efforts of these investigators have made compounds that are selective for different subtypes
of SK/IK channels available for the first time (table 1). There is no doubt that these compounds
will be used as pharmacological tools to discriminate the individual roles of SK/IK channel
subtypes in both physiological and pathophysiological conditions and may ultimately lead to
clinically useful therapeutic agents.
It is important to note that GW542573X is unique among the compounds described
above in that it has been described as a genuine SK1 channel opener [59]. In contrast, the
selective SK2/SK3 positive modulators can only potentiate SK/IK channel activity, and this
action requires the presence of Ca2+. This Ca2+-dependent mechanism is similar to that of the
nonselective SK/IK channel positive modulators (e.g., 1-EBIO and NS309) that cannot
activate the SK/IK channels without the presence of Ca2+. Accordingly, these compounds are
termed positive modulators because they enhance the Ca2+ sensitivity of the SK/IK channels.
It is this mechanism of action that led to the hypothesis that the binding site(s) for these
compounds lie(s) within the cytoplasmic region where CaM is associated with the channel.
However, the precise mechanism of action for these positive modulators has until recently
been unclear.
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a

PHU

b

1-EBIO

c

Fig. 2. Shared binding pocket
of multiple positive modulators.
Compounds such as PHU (a),
1-EBIO (b) and NS309 (c) bind at
the interface of CaM (gray surface) and the SK2-a channel fragment (light blue ribbon). Atoms in
the compounds are shown in the
following colors: carbon in yellow, oxygen in red, nitrogen in
blue and chloride in green. d Conformations of PHU, 1-EBIO and
NS309 are overlaid (PDB codes:
4G27, 4G28 and 4J9Z). The carbon atoms in the compounds are
shown in the following colors:
PHU in gray, 1-EBIO in cyan and
NS309 in magenta.

NS309

d

1-EBIO
PHU
NS309

SK2-a is an RNA splice variant of the SK2 channel. We have recently identified a novel SK2
alternative RNA splice variant of the SK2 channel, which was named SK2-b [4]. In a crystal
structure of the SK2-b channel fragment complexed with CaM (CaMBD2-b), we determined
that the small molecule phenylurea (PHU, a component of the crystallization solution) was
bound between CaM and the SK2-b channel fragment (fig. 2a). Electrophysiological measurements indicated that PHU can effectively potentiate the channel activity of both the SK2-a and
SK2-b splice variants. Interestingly, PHU exhibits slightly lower potency than the prototypical
positive modulator 1-EBIO [61].
The similarity in the chemical structures between PHU and the prototypical compound
1-EBIO [61] led us to test whether this binding site at the CaM-channel interface is the common
binding pocket for the positive modulators. This was done using a combination of approaches
including structural biology, computational biology and a functional assay [61]. In the crystal
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Fig. 3. Molecular basis for the
higher sensitivity of IK channels
to 1-EBIO compared with SK2-a
channels. a Amino acid sequences
of rat SK2-a and human IK channels at the region of the 1-EBIO
binding pocket were aligned. The
major SK2-a channel residues
that are required for 1-EBIO coordination (Ala477 and Leu480)
are highlighted in magenta. The
equivalent IK channel residues
(Val365 and Met368) are highlighted in blue. b The 1-EBIO
binding pocket of SK2-a with the
A477V/L480M double mutations.
The slightly bulkier residues in
the double mutant channel can
potentially form better contacts
with 1-EBIO. Green spheres: calcium ions.

a

477 480

Rat_SK2 469 EQRKLNDQANTLVDLAKTQ
Human_IK 357 KHRKLREQVNSMVDISKMH
b

CaM
N-lobe

1-EBIO
L480M
A477V

CaMBD

structure [Protein Data Bank (PDB) code: 4G28], 1-EBIO bound in a similar manner as PHU
at the interface of CaMBD2-a (from SK2-a) and the CaM N-lobe. 1-EBIO formed close contacts
with both CaM and CaMBD2-a (fig. 2b). The most potent SK channel positive modulator,
NS309 (fig. 2c), also binds into the same binding pocket as PHU and 1-EBIO (PDB code: 4J9Z).
These data strongly indicate that this interface is a shared binding site for SK/IK channel
positive modulators (fig. 2d).
Previous studies showed that IK channels are more sensitive to 1-EBIO than SK channels
[53]. An amino acid sequence alignment showed that IK channels contain unique residues at
the equivalent positions of A477 and L480 in SK2-a (fig. 3a). These residues are implicated in
the formation of the binding pocket for 1-EBIO (fig. 3b). In our recent report, a double SK2-a
mutant (A477V/L480M) was generated that mimics the corresponding residues in IK
channels. This SK2-a double mutant was more sensitive to potentiation by 1-EBIO mimicking
IK channels [61]. These data suggest that the binding pocket identified by crystallography is
indeed the functional binding site through which the compounds exert the positive modulation of channel activity.

A simplified chemomechanical gating scheme [2] of Ca2+-dependent SK channel activation might include two steps: (1) binding of Ca2+ to CaM associated with the SK/IK channel
and (2) mechanical coupling between Ca2+ binding to CaM and subsequent channel opening
(fig. 4). Positive modulators could therefore theoretically enhance either one of these two
steps in order to potentiate channel activity. To test this hypothesized mechanism, a biochemical binding assay was performed with NS309 [62]. In the presence of a saturating
NS309 concentration, no change was observed in the apparent Ca2+ affinity during formation
of the CaM/CaMBD complex. As a result, NS309 did not influence the first step of the hypothesized gating scheme, i.e., Ca2+ binding to the CaM-channel complex.
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CaM N-lobe
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We have recently identified a flexible region (R396-M412) in the SK2 channels that is
responsible for the second phase of the hypothesized step, i.e., mechanical coupling between
Ca2+ binding to CaM and subsequent channel opening. A previous report showed that the
SK2-a channel fragment located immediately after the transmembrane S6 domain, R396M412 (fig. 5a), was not visible in the CaM/CaMBD2-a crystal structure [2]. Our structure
determination, from multiple sets of X-ray diffraction data of the same complex, consistently
showed an interaction between the CaM linker and part of the missing fragment (E399-K402,
cuff; fig. 5b) instead of an interaction between the CaM linker and the poly-His tag used to
purify CaMBD2-a, as previously reported [2]. Most proteins form well-organized threedimensional structures to carry out their specific functions. On the other hand, intrinsically
disordered fragments (IDF) in proteins are equally important for protein function [63–65].
The channel fragment E404-M412, which connects the cuff and CaMBD, is visible neither in
our determined crystal structure (fig. 5b) nor in the previous report [2], suggesting this
fragment is an IDF.
The inherent flexibility of the IDF makes it a perfect motif for the regulation of protein
function, which, in this case, is SK/IK channel activity. Unfortunately, there was not enough
electron density to model the IDF in the crystal structures that were obtained in the presence
of the weak positive modulator 1-EBIO [61]. However, with the most potent modulator
NS309 [53], the IDF became readily identifiable (fig. 5c). The appearance of the IDF structure
in the presence of NS309 suggested that binding of NS309 to the protein complex might
stabilize IDF and consequently facilitate the transfer of conformational changes that occur
during Ca2+ binding to CaM to the mechanical opening of the channel (fig. 4). This mechanism
of action for NS309 was further confirmed with site-directed mutagenesis and electrophysiology [62].
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Fig. 4. A simplified chemomechanical gating scheme of SK/IK channels that was adapted from a previous
report [2]. The first step in channel activation is Ca2+ binding to CaM. Next, PIP2 mediates mechanical coupling
into the opening of the channel pore. For simplicity, only the S6 transmembrane domains from two channel
subunits are shown. The N-lobe of CaM is in red, while the C-lobe of CaM is in blue. PIP2 is shown in cyan. Ca2+
ions are shown as gray dots. Positive SK/IK channel modulators (e.g., NS309 or 1-EBIO) can enhance the mechanical coupling of Ca2+ binding into the channel opening. Conversely, phosphorylation of CaM by casein
kinase 2 can negatively modulate the PIP2-mediated mechanical coupling.
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Fig. 5. An IDF connects the CaMBD
to the SK/IK channel transmembrane S6 domain. The IDF is critical for the coupling of Ca2+ binding and the mechanical opening
of the channel. a Amino acid sequence alignment of SK/IK channels at the region that connects
the CaMBD and the S6 transmembrane domain. The amino acid
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In the past decade, it has been established that plasma membrane phosphoinositides
such as phosphatidylinositol 4,5-biphosphate (PIP2) can regulate the activities of many
different types of ion channels [66]. We recently demonstrated that SK channels are PIP2
sensitive [67]. The putative PIP2 binding site in the SK2/CaM complex involves the central
linker of CaM as well as the cuff and the IDF, which connects the transmembrane S6 domain
to the CaMBD. This region is implicated in the coupling of Ca2+ binding to CaM with the opening
of the SK channel pore [62]. A threonine residue (Thr79) in the CaM central linker that is
known to be phosphorylated by casein kinase 2 lies near the putative PIP2 binding site of the
SK2/CaM complex.
In general, interactions between channels and PIP2 are electrostatic in nature. The PIP2
binding sites consist of positively charged amino acid residues that are clustered close to
the bottom of the pore-forming S6 segments and the immediate C-linker region of the
channel that connects the S6 transmembrane domain to the cytosolic domain of the channel
proteins. The introduction of negative charges by phosphorylation at this site can effectively
reduce the apparent affinity of PIP2 for the channel complex and negatively modulate
channel activity, indicating that channel-PIP2 interactions are a critical element in channel
modulation.

Downloaded by:
Chapman University
198.143.33.33 - 7/16/2015 8:35:02 PM

The Possible Involvement of PIP2 in the Action of SK/IK Channel Positive
Modulators

75

Neurosignals 2014;22:65–78
DOI: 10.1159/000367896

© 2014 S. Karger AG, Basel
www.karger.com/nsg

Cui et al.: Targeting the Small- and Intermediate-Conductance Ca2+-Activated
Potassium Channels: The Drug-Binding Pocket at the Channel/Calmodulin Interface

The binding pocket for positive modulators (e.g., NS309) is adjacent to the PIP2 binding
site. However, no direct interaction between NS309 and PIP2 was indicated in the structural
model. Interestingly, the IDF residues Glu404 and Lys405 bridge the binding pockets for
NS309 and PIP2. This raises the exciting possibility that NS309 could allosterically affect
PIP2 binding to the CaM-SK channel complex. This hypothesis needs to be tested in the
future.

Riluzole is an FDA-approved drug that is used to prolong the survival of patients with
amyotrophic lateral sclerosis. Riluzole could exert its neuroprotective effects at least partly
through the positive modulation of SK channels [68]. Chlorzoxazone [69], a centrally acting
drug used to relieve muscle pain and stiffness, has also been found to positively modulate SK
channels. Both drugs are being evaluated for ataxia [17] and alcohol use disorders [27] in
clinical trials targeting SK channels for new clinical applications. However, neither riluzole
nor chlorzoxazone exhibit satisfactory potency [53]; on the one hand, this reflects the need
for SK channel modulators as therapeutic agents and, on the other hand, the lack of new
modulators as drug candidates.
Despite the recent progress in our understanding of the structural biology of ion channels,
the structure of SK/IK channel transmembrane domains is not yet available. This deficiency
could make the structure-based discovery of new drugs that target the channel pore region a
difficult task. However, the Ca2+ gating domains (CaM and CaMBD) from two alternative splice
variants of SK2 channels (SK2-a and SK2-b) have been crystallized [2–4]. This opens the
possibility of an accelerated development of SK channel positive modulators. Importantly, the
SK2-b variant differs from SK2-a by only an insertion of three amino acid residues in the
CaMBD. Nonetheless, this difference is enough to force CaM to adopt a completely different
conformation when complexed with either variant. Because the two variants exhibit a significantly different Ca2+ sensitivity for activation [4], these data suggest a critical role of the Ca2+
gating domain (CaM/CaMBD complex) in regulating SK/IK channel activity. Accordingly,
these observations raise the question of whether it is possible to develop novel SK/IK channel
modulators by targeting the CaM/CaMBD region. Importantly, positive modulators have been
shown to bind at the CaM/CaMBD interface. This drug-binding pocket for SK/IK channel
positive modulators is shared by multiple compounds with different potency, including PHU,
1-EBIO and NS309 (fig. 2). A systematic analysis of the CaM/CaMBD structure complexed
with various compounds could reveal the structural determinants for drug potency. These
studies are crucial in the structure-based discovery of more potent modulators. For example,
a recent structure-activity relationship study conducted by Dr. Wulff’s group led to the potent
IK channel-selective modulator SKA-111 [60]. That effort was a very exciting example of
rational drug discovery targeting SK/IK channels that was aided by structural information.
As such, structural insights may not only help improve the potency of positive modulators,
but this information may also be useful in the identification of modulators that exhibit more
subtype selectivity.
While positive modulators have been hypothesized to potentiate SK/IK channels through
enhancing Ca2+ binding to CaM since the early years of their discovery, recent research has
indicated that NS309 does not influence the Ca2+-dependent formation of the CaM/CaMBD
complex [62]. Instead, the binding of NS309 stabilizes an IDF that connects the CaMBD to the
transmembrane domains. In this model, NS309 acts as a positive modulator via enhancing the
second hypothesized step (coupling) rather than the first step (Ca2+ binding) of the gating
scheme (fig. 4). This mechanism of action might also apply to other SK/IK channel positive
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modulators such as 1-EBIO. It is also a fair question to ask whether negative modulators could
be developed by differentially targeting the same binding pocket. In other words, a negative
modulator could change the IDF into an unfavorable conformation, which would reduce the
efficiency of coupling to channel opening.
Lastly, CaM has been implicated in the modulation of many ion channels including
voltage-gated Na+ and Ca2+ channels [70]. Thus, it would be interesting to investigate whether
the interface of CaM and these ion channels could also accommodate the pharmacological
modulation by small molecules. If true, this could lead to novel strategies for targeting voltagegated Na+ and Ca2+ channels.
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